Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Paul Moore
A Phase I, First-In-Human, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Development of PF-06671008, a Highly Potent Anti-P-Cadherin/Anti-Cd3 Bispecific DART Molecule With Extended Half-Life for the Treatment of Cancer
Antibodies
Drug Discovery
Allergy
Immunology
Related publications
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies
Cancer
Cancer Research
Oncology
A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine
British Journal of Cancer
Cancer Research
Oncology
DUAL PI3K Δ/Γ INHIBITOR RP6530 IN PATIENTS WITH RELAPSED/REFRACTORY T-Cell LYMPHOMA: DOSE ESCALATION FINDINGS.
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
First-In-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-In-Class Dual MEK/RAF Inhibitor in Patients With Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies
Clinical Cancer Research
Cancer Research
Oncology
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
First-In-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-Her3 Monoclonal Antibody, in Patients With Metastatic or Advanced HER3-Positive Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
